UY25950A1 - Procedimiento para preparar composiciones de tratamiento oral para la prevencion de la resorcion osea - Google Patents

Procedimiento para preparar composiciones de tratamiento oral para la prevencion de la resorcion osea

Info

Publication number
UY25950A1
UY25950A1 UY25950A UY25950A UY25950A1 UY 25950 A1 UY25950 A1 UY 25950A1 UY 25950 A UY25950 A UY 25950A UY 25950 A UY25950 A UY 25950A UY 25950 A1 UY25950 A1 UY 25950A1
Authority
UY
Uruguay
Prior art keywords
same
treatment
prevention
resorption
oral
Prior art date
Application number
UY25950A
Other languages
English (en)
Spanish (es)
Inventor
Anastasia G Daifotis
Arthur C Santora Ii
A John Yates
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY25950(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9717590.5A external-priority patent/GB9717590D0/en
Priority claimed from GBGB9717850.3A external-priority patent/GB9717850D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of UY25950A1 publication Critical patent/UY25950A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
  • Pit Excavations, Shoring, Fill Or Stabilisation Of Slopes (AREA)
  • Aiming, Guidance, Guns With A Light Source, Armor, Camouflage, And Targets (AREA)
  • Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
UY25950A 1997-07-22 2000-01-17 Procedimiento para preparar composiciones de tratamiento oral para la prevencion de la resorcion osea UY25950A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5335197P 1997-07-22 1997-07-22
US5353597P 1997-07-23 1997-07-23
GBGB9717590.5A GB9717590D0 (en) 1997-08-20 1997-08-20 Oral method for treating or preventing abnormal bone resorption
GBGB9717850.3A GB9717850D0 (en) 1997-08-22 1997-08-22 Oral method for treating or preventing abnormal bone resorption

Publications (1)

Publication Number Publication Date
UY25950A1 true UY25950A1 (es) 2000-09-29

Family

ID=27451690

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25950A UY25950A1 (es) 1997-07-22 2000-01-17 Procedimiento para preparar composiciones de tratamiento oral para la prevencion de la resorcion osea

Country Status (31)

Country Link
EP (5) EP0998292B1 (enExample)
JP (2) JP3479780B2 (enExample)
KR (3) KR20030097611A (enExample)
CN (3) CN1602879A (enExample)
AT (2) ATE357921T1 (enExample)
AU (1) AU8493698A (enExample)
BG (1) BG66282B1 (enExample)
BR (1) BR9810779A (enExample)
CA (1) CA2294595C (enExample)
CY (2) CY1107535T1 (enExample)
DE (6) DE122006000009I1 (enExample)
DK (2) DK1175904T3 (enExample)
EA (1) EA004544B2 (enExample)
EE (1) EE05603B1 (enExample)
ES (3) ES2253136T1 (enExample)
HK (4) HK1042230A1 (enExample)
ID (1) ID24096A (enExample)
IL (1) IL133535A0 (enExample)
IS (3) IS5315A (enExample)
LU (2) LU91222I2 (enExample)
NL (2) NL300223I1 (enExample)
NO (1) NO20000323L (enExample)
NZ (1) NZ501807A (enExample)
PL (1) PL195272B1 (enExample)
PT (2) PT1175904E (enExample)
SG (2) SG139556A1 (enExample)
SI (1) SI0998292T1 (enExample)
SK (1) SK932000A3 (enExample)
TR (1) TR200000145T2 (enExample)
UY (1) UY25950A1 (enExample)
WO (1) WO1999004773A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69916326T2 (de) * 1998-12-25 2005-03-17 Yamanouchi Pharmaceutical Co., Ltd. Medizinische zusammensetzungen zur behandlung von knochenschäden im multiplen myelom
NZ515541A (en) * 1999-05-21 2003-03-28 Novartis Ag Pharmaceutical compositions comprising bisphosphonates to treat angiogenesis
CN100349574C (zh) * 1999-07-19 2007-11-21 东丽株式会社 牙周疾病用剂
WO2001046040A1 (en) 1999-12-20 2001-06-28 Merck & Co., Inc. Blister package for pharmaceutical treatment card
IL142515A0 (en) * 1999-12-20 2002-03-10 Merck & Co Inc Pharmaceutical kit
MXPA02009924A (es) * 2000-04-07 2004-08-19 Univ Texas Composiones unicas de fosfolipidos de ion anfoterico y bisfosfonatos y uso de las composiciones como sistemas de suministro de bisfosfato con toxicidad gi reducida.
DE60113537T3 (de) 2000-06-20 2013-05-29 Novartis Ag Methode zur verabreichung von biphosphonaten
RU2288722C2 (ru) * 2000-06-20 2006-12-10 Новартис Аг Способ введения бисфосфонатов
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
JP2004528365A (ja) * 2001-05-02 2004-09-16 ノバルティス アクチエンゲゼルシャフト 骨再吸収症および骨粗しょう症の処置または予防におけるビスホスホネートの吸入投与方法
DE60317061T2 (de) * 2002-05-10 2008-07-24 F. Hoffmann-La Roche Ag Ibandronsäure zur behandlung und vorbeugung von osteoporose
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
NZ545804A (en) * 2003-09-19 2009-09-25 Wisconsin Alumni Res Found Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-or-vitamin D derivatives and a bisphosphonate
WO2005072747A1 (ja) * 2004-02-02 2005-08-11 Ono Pharmaceutical Co., Ltd. 骨吸収抑制剤
EP1937362B1 (en) * 2005-09-16 2013-03-27 Selamine Ltd. Bisphosphonate formulation
KR20170104664A (ko) * 2010-12-06 2017-09-15 에프락스 파머슈티컬즈 소시에떼 아노님 신속한 용해 특성을 구비한 안정한 발포성 비스포스포네이트 제형
CN106924257B (zh) * 2017-03-14 2019-11-19 湖南赛隆药业有限公司 质子泵抑制剂和抗骨质疏松药的复合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84731A0 (en) * 1986-12-19 1988-05-31 Norwich Eaton Pharma Heterocycle-substituted diphosphonic acids and salts and esters and pharmaceutical compositions containing them
SE8704436D0 (sv) * 1987-11-13 1987-11-13 Pm Konsult Handelsbolag Anvendning av antisekretoriska substanser for nya indikationer
ES2074769T3 (es) * 1991-07-01 1995-09-16 Gergely Gerhard Procedimiento para la elaboracion de un preparado farmaceutico con, al menos, dos principios activos diferentes y uso de un preparado de este tipo.
CA2122479C (en) * 1991-11-22 1998-08-25 Richard John Dansereau Risedronate delayed-release compositions
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
DK0648120T3 (da) * 1992-06-30 1998-01-19 Procter & Gamble Pharma Anvendelse af phosphonater til behandling af osteoporose
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
JPH11506750A (ja) * 1995-06-06 1999-06-15 メルク エンド カンパニー インコーポレーテッド 慢性関節リウマチに係わる骨欠損に対するビスホスホネート療法
ATE256456T1 (de) * 1996-05-17 2004-01-15 Merck & Co Inc Biphosphonat-formulierung mit brausewirkung

Also Published As

Publication number Publication date
CA2294595C (en) 2001-08-21
IS5315A (is) 1999-12-21
NO20000323L (no) 2000-03-20
EP1175904A2 (en) 2002-01-30
CY2007022I2 (el) 2012-01-25
KR20010022110A (ko) 2001-03-15
ATE357921T1 (de) 2007-04-15
JP2005068010A (ja) 2005-03-17
EP1175903A2 (en) 2002-01-30
CY1107535T1 (el) 2012-01-25
EA004544B2 (ru) 2006-12-29
CN1265035A (zh) 2000-08-30
KR20030097610A (ko) 2003-12-31
BR9810779A (pt) 2000-07-25
KR20030097611A (ko) 2003-12-31
DE01201911T1 (de) 2007-10-18
DE69803291T2 (de) 2002-08-08
LU91222I2 (fr) 2006-04-18
CY2007022I1 (el) 2012-01-25
WO1999004773A2 (en) 1999-02-04
NL300292I1 (nl) 2007-11-01
EA200000151A1 (ru) 2000-10-30
PL338635A1 (en) 2000-11-06
EP1132088A3 (en) 2002-04-24
CN1166365C (zh) 2004-09-15
SI0998292T1 (en) 2002-04-30
HK1040494A1 (en) 2002-06-14
LU91364I2 (fr) 2007-11-12
WO1999004773A9 (en) 1999-10-28
NO20000323D0 (no) 2000-01-21
SG139556A1 (en) 2008-02-29
BG66282B1 (bg) 2013-01-31
CN1299689C (zh) 2007-02-14
HK1040495A1 (en) 2002-06-14
EE200000040A (et) 2000-10-16
DE01201913T1 (de) 2007-02-08
DE122006000009I1 (de) 2006-06-14
BG104093A (en) 2000-10-31
EP1151752A3 (en) 2002-12-18
EP1175904B1 (en) 2007-03-28
EP1132088A2 (en) 2001-09-12
HK1024166A1 (en) 2000-10-05
EE05603B1 (et) 2012-12-17
DE69803291D1 (de) 2002-02-21
TR200000145T2 (tr) 2000-05-22
SG109478A1 (en) 2005-03-30
ES2269014T3 (es) 2007-05-01
DK1175904T3 (da) 2007-05-07
PT998292E (pt) 2002-04-29
KR100391732B1 (ko) 2003-07-16
CA2294595A1 (en) 1999-02-04
CN1602880A (zh) 2005-04-06
HK1042232A1 (en) 2002-08-09
EP0998292A2 (en) 2000-05-10
EA004544B1 (ru) 2004-06-24
CN1602879A (zh) 2005-04-06
ES2269014T1 (es) 2007-04-01
NL300223I1 (nl) 2006-04-03
IS7231A (is) 2004-04-21
EP1175904B8 (en) 2007-05-09
IL133535A0 (en) 2001-04-30
EP1151752A2 (en) 2001-11-07
EP1175904A3 (en) 2002-12-18
NZ501807A (en) 2003-02-28
DE69837450D1 (de) 2007-05-10
EP1175903A3 (en) 2002-12-18
JP3479780B2 (ja) 2003-12-15
IS7230A (is) 2004-04-21
AU8493698A (en) 1999-02-16
PL195272B1 (pl) 2007-08-31
ES2253136T1 (es) 2006-06-01
HK1042230A1 (en) 2002-08-09
EP0998292B1 (en) 2001-11-21
ES2164447T3 (es) 2002-02-16
PT1175904E (pt) 2007-04-30
JP2002502433A (ja) 2002-01-22
ID24096A (id) 2000-07-06
DE69837450T2 (de) 2007-08-23
WO1999004773A3 (en) 1999-04-15
SK932000A3 (en) 2000-09-12
ATE209037T1 (de) 2001-12-15
DK0998292T3 (da) 2002-05-13
DE122007000063I1 (de) 2007-12-20

Similar Documents

Publication Publication Date Title
UY25950A1 (es) Procedimiento para preparar composiciones de tratamiento oral para la prevencion de la resorcion osea
US5853759A (en) Effervescent alendronate formulation
CA2254060C (en) Effervescent bisphosphonate formulation
ES2247123T7 (es) Método para administrar bisfosfonatos
RU94046316A (ru) Применение высокоэффективных фосфонатов при изготовлении лекарственных средств для лечения остеопороза
YU31795A (sh) Oralne tečne formulacije alendronata
JPH08505142A (ja) 骨損失を治療及び予防するためのビスホスホネート／エストロゲン療法
RU2008103617A (ru) Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза
RU2006126783A (ru) Фармацевтические составы бисфосфонатов
DK0833643T3 (da) Formuleringer af vandfrit mononatriumsalt af alendronat og deres anvendelse til behandling af knoglesygdomme
RU94045950A (ru) Фармацевтический препарат и способ его приготовления
ES2129485T3 (es) Derivados de acidos guanidinoalquil-1,1-bisfosfonicos, procedimiento para su preparacion y su utilizacion.
CA2294101A1 (en) A combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor
KR970061249A (ko) 골다공증을 치료 또는 방지하기 위한 조성물
MX9303243A (es) Compuestos de fosfonato novedosos que contienen nitrogeno cuaternario, composiciones farmaceuticas y metodos para tratar el metabolismo anormal del calcio y el fosfato, y metodos para tratar y prevenir calculos dentales y placa dental.
McClung Bisphosphonates
US6399592B1 (en) Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss
ES2262145T3 (es) Composicion anabolica para la masa osea que comprende olpadronato.
ES2182504T3 (es) Bifenilsulfonilcianamidas, procedimiento para su preparacion y su utilizacion como medicamento.
RU2004122433A (ru) Способ лечения костных нарушений
US20060034921A1 (en) Effervescent bisphosphonate formulation
US20040137058A1 (en) Effervescent bisphosphonate formulation
AR013500A1 (es) Uso de acido alendronico o una sal farmaceuticamente aceptable del mismo o una mezcal de los mismos para la manufactura de un medicamento
Moradi et al. Evaluation of Jaw Osteonecrosis Following Intra-Ligament Anesthesia in Zoledronate-Treated Rats: a Histological Evaluation
AR017240A2 (es) COMPOSICIONES DE ÁCIDO ALENDRoNICO , SUS SALES O ESTERES

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20041115